9 Biotechnology Stocks to Buy Now

by Portfolio Grader | December 11, 2013 12:00 pm

This week, nine biotechnology stocks are improving their overall rating on Portfolio Grader[1]. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).

PharmAthene, Inc. (PIP[2]) ups its rating to a B (“buy”) this week after earning a C (“hold”) in the week before. PharmAthene develops biological and chemical defense products. For more information, get Portfolio Grader’s complete analysis of PIP stock[3].

Puma Biotechnology, Inc. (PBYI[4]) is making headway this week, with the company’s rating improving to an A (“strong buy”) from a B (“buy”) last week. Puma Biotechnology engages in the acquisition, development, and licensing of products for the treatment of various forms of cancer. Shares of PBYI have increased 145.2% over the past month, better than the 1.7% decrease the S&P 500 has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of PBYI stock[5].

The rating of Idera Pharmaceuticals, Inc. (IDRA[6]) moves up this week, rising from a B to an A. Idera Pharmaceuticals is engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-Like Receptors (TLRs) to treat infectious diseases, autoimmune and inflammatory diseases, cancer, asthma and allergies, and for use as vaccine adjuvants. For more information, get Portfolio Grader’s complete analysis of IDRA stock[7].

This week, ARIAD Pharmaceuticals, Inc.’s (ARIA[8]) ratings are up from a C last week to a B. ARIAD Pharmaceuticals is an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients. For more information, get Portfolio Grader’s complete analysis of ARIA stock[9].

Evogene Ltd (EVGN[10]) is seeing ratings go up from a B last week to an A this week. Evogene engages in the development of enhanced plant traits through the use of plant genomics. For more information, get Portfolio Grader’s complete analysis of EVGN stock[11].

This week, Neurocrine Biosciences, Inc. (NBIX[12]) pushes up from a C to a B rating. Neurocrine Biosciences is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. For more information, get Portfolio Grader’s complete analysis of NBIX stock[13].

Array BioPharma (ARRY[14]) shows solid improvement this week. The company’s rating rises from a C to a B. Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. For more information, get Portfolio Grader’s complete analysis of ARRY stock[15].

Celldex Therapeutics, Inc. (CLDX[16]) gets a higher grade this week, advancing from a B last week to an A. Celldex Therapeutics is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. For more information, get Portfolio Grader’s complete analysis of CLDX stock[17].

Insmed Incorporated (INSM[18]) boosts its rating from a C to a B this week. Insmed develops and commercializes drugs that treat metabolic diseases, endocrine disorders and oncology. For more information, get Portfolio Grader’s complete analysis of INSM stock[19].

Louis Navellier’s proprietary Portfolio Grader[20] stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here[21].

Source URL: https://investorplace.com/2013/12/9-biotechnology-stocks-to-buy-now-pip-pbyi-idra/

---